RECURRENT MALIGNANT GLIOMA
Clinical trials for RECURRENT MALIGNANT GLIOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MALIGNANT GLIOMA trials appear
Sign up with your email to follow new studies for RECURRENT MALIGNANT GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…
Matched conditions: RECURRENT MALIGNANT GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Targeted drug shows promise for kids with tough cancers
Disease control CompletedThis study tested a drug called palbociclib in 23 children and young adults (ages 1–21) whose cancers had come back or didn't respond to treatment. The drug works by blocking proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the disease i…
Matched conditions: RECURRENT MALIGNANT GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo targets recurrent brain tumors in early trial
Disease control CompletedThis phase 1 trial tested a combination of two drugs, ASP8374 and cemiplimab (Libtayo), in 14 people with recurrent malignant glioma, a type of brain cancer. The study had two parts: first, finding the safest dose of ASP8374 when given with cemiplimab, and second, checking how th…
Matched conditions: RECURRENT MALIGNANT GLIOMA
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC